Nomir Medical to Present Positive In Vitro Data on Antibacterial Properties of its Noveon® Dual-Wavelength Optical Energy Device

-Full Data to be Presented at the American Society for Laser Medicine and Surgery 2009 Annual Conference-

Waltham, MA – April 2, 2009 – Nomir Medical Technologies, a leader in the development of optical energy technologies for anti-infective medical applications, announced today that the Company will present an abstract detailing two years of successful scientific research into the antibacterial action spectrum of its Noveon® dual-wavelength optical antimicrobial system. The antimicrobial action spectrum experiments demonstrate that the Noveon patented and proprietary 870nm/930nm wavelengths are more effective at inactivating pathogens than other near-infrared wavelength combinations that were tested. The Noveon is designed to cause photo-damage in bacterial and fungal pathogens and is the first known device to do so at temperatures that are safe to normal and healthy tissue.

The detailed data will be presented at LASER ’09, the American Society for Laser Medicine and Surgery 2009 Annual Conference, in National Harbor, MD, at 5:00 pm Friday, April 3, 2009 in the Photobiomodulation Session. Data and further background regarding the Noveon device will also be available in Nomir’s exhibit booth #927 on April 3rd and 4th.

Nomir has completed three successful IRB-approved human studies against onychomycosis (toenail fungus) and two successful IRB-approved human studies against methicillin-resistant Staphylococcus aureus (MRSA) carriage and infection in the nares (nose) with Noveon. The Company recently reached study endpoints in its FDA pivotal study for the treatment of onychomycosis and plans to submit its data for an FDA 510(k) clearance of this indication.

Based on the successful outcomes of all of these studies, Nomir plans to initiate a proof-of-concept study for the Noveon therapy for the reduction of bioburden in diabetic foot ulcers.

About Nomir
Nomir Medical Technologies, Inc. is a medical device company with a product pipeline of optical energy therapeutics being developed for multiple clinical applications. Nomir’s light-based systems target the elimination of bacterial and fungal infections, while also promoting healthy tissue recovery. This potential therapy-altering technology may enhance the effectiveness of, or even reduce the need for antibiotics and antifungal agents, and may be associated with fewer treatment side-effects. Nomir has a broad patent portfolio with pending systems, methods and unique photobiological mechanism claims for near-infrared photo-damage to bacterial and fungal pathogens. www.nomirmedical.com

Forward-looking statements
Certain statements contained in this press release containing words like believe, intend, may, expect, project and other similar expressions are forward-looking statements involving a number of risks and uncertainties. Factors that can cause actual results to differ materially from those projected in the Company’s forward-looking statements include the following: market acceptance of our technologies, therapies, and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapidly changing technologies; government regulations of our technologies; our ability to assert and enforce our intellectual property rights and protect our proprietary technologies; the ability to attract and retain key employees; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key milestones in key products and other risks factors from time to time in the Company’s announcements.

Contacts:
Media: MacDougall Biomedical Communications
Jennifer Greenleaf-Conrad
(781) 235-3060

Richard Burtt
Chief Executive Officer
Nomir Medical Technologies, Inc.
(781) 893-1000 ext. 403

# # #